



# Exercise 1

Feb 28<sup>th</sup> 2025

Q1: Which one of the following options does **NOT** play a role in monoclonal antibody production by Hybridoma technology?

- A. Antigen-specific T cells
- B. Antigen-specific B cells
- C. Myeloma cells
- D. Culturing in HAT medium

Q2: By using an ELISA kit for the detection of IFN-gamma among different treatments of T cells in one experiment, we will **NOT** be able to detect:...

- A. The presence of IFN- $\gamma$  in different treatments
- B. The purity of IFN- $\gamma$  among other cytokines in different treatments
- C. The quantity of IFN- $\gamma$  in different treatments
- D. We can detect all above-mentioned options

Q3: To perform an ELISA, which options shows the correct sequence to add reagents to the immune-plate?

- A. HRP-Streptavidin → Biotin-labelled detection Ab  
→ Sample → Capture Ab → TMB substrate
- B. Capture Ab → Sample → Biotin-labelled detection  
Ab → HRP-Streptavidin → TMB substrate
- C. Sample → Capture Ab → Biotin-labelled detection  
Ab → HRP-Streptavidin → TMB substrate
- D. Capture Ab → Sample → HRP-Streptavidin →  
Biotin-labelled detection Ab → TMB substrate

## Q4: Clonal expansion of OVA-specific B cells can be done by:

- A. Soluble ovalbumin
- B. MHC I-bound ovalbumin peptides
- C. MHC II-bound ovalbumin peptides
- D. OVA-reactive T cells

Q5: The transcript profile of T cells can be identified by:

- A. RT-qPCR
- B. ELISPOT
- C. Flow cytometry
- D. Mass spectrometry

Q6: In a mixture of CD4+ T cells, CD8+ T cells and B cells, we can identify all T cells by the expression of:

- A. CD3
- B. CD4
- C. CD8
- D. Tetramer